Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naïve individuals.

Margot NA, Ram RR, White KL, Abram ME, Callebaut C.

J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.

PMID:
31389026
2.

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.

Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD.

J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.

PMID:
28453836
3.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD.

PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.

4.

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.

Margot NA, Liu Y, Miller MD, Callebaut C.

Antiviral Res. 2016 Aug;132:50-8. doi: 10.1016/j.antiviral.2016.05.012. Epub 2016 May 18.

PMID:
27208653
5.

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C.

HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.

PMID:
26892863
6.

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro.

Margot NA, Johnson A, Miller MD, Callebaut C.

Antimicrob Agents Chemother. 2015 Oct;59(10):5917-24. doi: 10.1128/AAC.01151-15. Epub 2015 Jul 6.

7.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

8.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

9.

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD.

Antiviral Res. 2012 Feb;93(2):288-296. doi: 10.1016/j.antiviral.2011.12.008. Epub 2011 Dec 16.

PMID:
22197635
10.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.

Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, Miller MD, Svarovskaia ES.

AIDS. 2011 Jan 28;25(3):325-33. doi: 10.1097/QAD.0b013e3283427dcb.

PMID:
21157296
11.

Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.

Margot NA, Gibbs CS, Miller MD.

Antimicrob Agents Chemother. 2010 Jun;54(6):2345-53. doi: 10.1128/AAC.01784-09. Epub 2010 Mar 22.

12.

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.

Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ; Study 934 Team.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):209-21. doi: 10.1097/QAI.0b013e3181b05f7c.

PMID:
19644384
13.

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Svarovskaia ES, Feng JY, Margot NA, Myrick F, Goodman D, Ly JK, White KL, Kutty N, Wang R, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):428-36. doi: 10.1097/QAI.0b013e31817bbe93.

PMID:
18614922
14.

The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.

Ly JK, Margot NA, MacArthur HL, Hung M, Miller MD, White KL.

Antivir Chem Chemother. 2007;18(6):307-16.

PMID:
18320935
15.

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):174-80.

PMID:
17667333
16.

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.

Marchand B, White KL, Ly JK, Margot NA, Wang R, McDermott M, Miller MD, Götte M.

Antimicrob Agents Chemother. 2007 Aug;51(8):2911-9. Epub 2007 May 21.

17.
18.

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Margot NA, Waters JM, Miller MD.

Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. Epub 2006 Sep 18.

20.

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.

White KL, Chen JM, Feng JY, Margot NA, Ly JK, Ray AS, Macarthur HL, McDermott MJ, Swaminathan S, Miller MD.

Antivir Ther. 2006;11(2):155-63.

PMID:
16640096
21.

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B.

Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107.

PMID:
16440988
22.

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.

White KL, Margot NA, Ly JK, Chen JM, Ray AS, Pavelko M, Wang R, McDermott M, Swaminathan S, Miller MD.

AIDS. 2005 Nov 4;19(16):1751-60.

PMID:
16227782
23.
24.

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.

McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1340-50.

PMID:
15483463
25.
26.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
27.
28.
29.

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD.

AIDS. 2002 Jun 14;16(9):1227-35.

PMID:
12045487
30.

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.

Naeger LK, Margot NA, Miller MD.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):635-9.

PMID:
11563081
31.

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Miller MD, Margot NA, Hertogs K, Larder B, Miller V.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1025-8.

PMID:
11562951
32.

Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):450-8.

PMID:
11511821
34.

In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.

Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM.

Antivir Ther. 1999;4(2):87-94.

PMID:
10682153
35.

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, Tarara RP, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC.

J Virol. 2000 Feb;74(4):1767-74.

36.

Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.

Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM.

Mol Pharmacol. 1998 Aug;54(2):291-7.

PMID:
9687570

Supplemental Content

Loading ...
Support Center